Frontage Laboratories, Inc., a global CRO/CDMO, completed the acquisition of Teddy Clinical Research Laboratory (Shanghai), Ltd. (Teddy Lab), a clinical research laboratory service provider in China. The acquisition aims to enhance Frontage’s global laboratory service capabilities and further strengthen its presence in China and the Asia-Pacific region.

Teddy Lab has extensive experience supporting more than 1,500 clinical trials across multiple therapeutic areas. The company is known for its GCP-compliant operations and internationally accredited laboratory services. Teddy Lab operates under CAP-accredited and NGSP Level 1 certified quality systems, as well as qualification as a Class II Unsealed Radioactive Material Workplace. Its track record includes supporting regulatory inspections and contributing to the successful marketing approval of 50 new drugs.

As a result of the transaction, Frontage has expanded its central laboratory footprint in China, which it expects to leverage in supporting the increasing demand for both domestic China and multi-regional clinical trials (MRCT). 

The acquisition further supports our role as a “one-stop shop” in delivering high-quality drug development services to pharmaceutical companies, biotechnology firms, contract research organizations, and research institutions worldwide. We anticipate that our continued investment in expanding our global infrastructure and scientific capabilities will help us meet the evolving needs of the life sciences industry.